Preparing a US FDA Medical Device 510(K) Submission

Size: px
Start display at page:

Download "Preparing a US FDA Medical Device 510(K) Submission"

Transcription

1 Preparing a US FDA Medical Device 510(K) Submission If you want to introduce your medical device to the US market, you need to obtain clearance from the FDA. This clearance is obtained from the FDA via a 510(k) submission, also known as Pre-Market Notification. Below are the steps that will be explained in details later on; Step (1): Medical device confirmation and Classification Step (5): Clearance and Registration Step (2): Predicate device finding Step (4): Preparation and Submission of 510(k) application Step (3): Application standard/guidanc e Documents Identification The New 510(k): Recent changes to the process: The 510(k) process became more complicated and time consuming due to the following reasons; The FDA obligated and approved a more structured approach to 510(k) submissions, which includes submission of both paper and electronic copies. The submission must pass the ecopy test before the FDA will accept the submission. The FDA placed the Refuse-to-Accept process, which is intended to assure that the requested data and documents of a 510(k) submission are present and correctly submitted.180 days will be given to correct faults and complete missing data identified in a RTA letter. The FDA reviewers typically subdivide the submission to various sub-reviewers. These sub-reviewers are evaluating the 510(k) submission much more closely than in the past. Before, simply stating that this work was done or providing a high-level summary was

2 sufficient. Now, the FDA is carefully reviewing the actual data and check the details of how it is done. The agency also uses the Additional Information Required (AI) process to request more information. However, the agency recently adopted a one-response requirement for AIs, in which sponsors receive one opportunity to address the FDA s concerns or requests for additional information. Should that response be inadequate or incomplete, the submission may be deleted. Now, we will go through the steps of the 510(k) process in details. Also, we will review the most common mistakes that may delay the 510(k) registration. Step (1): Medical Device Confirmation and Clarification: The first step to obtaining FDA 510(k) clearance is to make sure your product qualifies as a medical device. The definition of a medical device from the Federal Food, Drug, and Cosmetic Act (FD&C) is a product that: 1) Is recognized in the national formulary as a device (rare). 2) Is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. 3) Is intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purpose through mechanical action within or on the body. Items 2 and 3 are usually the most relevant. If a product meets the legal definition of a device, then you must determine its classification by searching the device type on the FDA classification database. The FDA s Classification System Divides Medical Devices into Three Classes: Class I: devices posing the lowest risk to patients or users Class II: devices that could harm patients or users if used improperly or malfunction Class III: devices that could severely injure or kill patients or users if used improperly or malfunction. For the most part, Class I devices do not require FDA pre-market clearance or approval for sale in the US. Yet, Class I device manufacturers must still register their products with the agency. Most Class II devices, however, must go through the FDA 510(k) process, while nearly all highrisk Class III devices go through the more rigorous premarket approval (PMA) process. Step (2): Predicate device finding: Market approval in the US is based on establishing substantial equivalence with another cleared device. This requires manufacturers to identify another device already on the market that shares the same intended use and is technologically similar to the device they wish to market. Once the product code is identified, the FDA s 510(k) database can be searched for products that have been cleared under that code. After you find devices that might be useful as predicates, download the 510(k) Summary for each potential predicate (available through the 510(k) database). This document provides the exact indications for use, a summary of the technological features, and sometimes even a list of the testing that was conducted.

3 Key Points: 1. Select the predicate device with identical indications for use (or as close as you can find). 2. Select the predicate device that employs similar technology to yours. 3. Newer clearances are usually better choices than older clearances. Step (3): Application Standard/Guidance Documents Identification: This is one of the more difficult tasks when mapping out a 510(k) submission. Unfortunately, the FDA does not provide a complete and comprehensive list of what may be required. However, there are several sources you should consult: 1. Product code information: By searching the product code identified in FDA production classification, this will return a lot of useful information, including specific standards, FDA Guidance Documents for this device, the risk class (Class II etc.), and confirmation of the CFR reference for the product code. 2. Special guidance and international standards: Determine if any special regulatory guidance documents or international standards apply to your device using the 510(k) clearance letter. These may include software validation, electrical safety, or other standards. 3. Biocompatibility testing: It is often required for devices or parts of devices to determine the potential toxicity resulting from contact with the user. FDA recognizes the series of ISO standards for biological evaluation of medical devices, which provides guidance for selecting the necessary tests 4. Guidance documents: Search the FDA website for applicable guidance documents. Carefully follow the recommendations set forth in guidance documents to ensure a successful submission to the FDA. 5. Software or firmware: The FDA recently changed the validation requirements for software or firmware that may be used with the device. The validation requirement is not new, but its application to simple firmware is a new requirement. Unless your firmware is very basic, expect to validate the software to the moderate level of concern. 6. Clinical data: The agency may require a clinical study in cases where the agency does not feel the technology of the subject device is close enough to the predicate device. Clinical research has its own requirements and failure to follow these can invalidate your study or lead to significant penalties. 7. Usability studies: It demonstrates that the user can read and understand the directions and use the device correctly. For products intended to be sold over-the-counter, the FDA also wants a demonstration that the expected user can correctly select the product.

4 Step (4):Preparation and Submission of 510K application: There is some flexibility on how a 510(k) may be assembled for submission to the FDA. However, the FDA is fairly strict about how the application is organized. A common process utilizes 20 individual sections, each addressing a specific 510(k) requirement. Most 510(k)s are well over 100 pages and must also meet the FDA s ecopy submission requirements to be accepted for review. Once you have identified your predicate device and finalized all safety and performance Testing for your product in comparison to your predicate, you must begin preparing your 510(k) application for submission to the FDA for review. The FDA timeframe for 510(k) review is 90 working days. The 90-day review clock stops in the event of a Refuse-to-Accept (RTA) letter or an Additional Information Required (AI) letter. Sponsors have 180 days to resolve RTA issues. Note that if responses are not received during the 180-day time frame, the FDA will delete the submission without refunding the user fee. Generally, you should plan for the 510(k) submission to take no less than 4-6 months. Common mistakes that can delay FDA 510(k) reviews: As discussed, there are two places where the 510(k) process can come to a halt. The first is the RTA process which is used when a submission does not contain all of the required information. This can result in a significant delay. The other major impact to the successful clearance of your 510(k) is the AI Letter. Common Issues that can result an AI Common Issues Details All 510(k) submissions must include accurate descriptions of how the device is intended to function. An incomplete or inaccurate description will prevent FDA reviewers from determining if your device has been properly evaluated; Inadequate Device description reviewers will also be unable to determine if your documentation supports your device s intended use. You must include a thorough and accurate description of your device to ensure a substantive FDA review of your 510(k) submission. 510(k) submissions are highly redundant the same information appears in multiple sections throughout the document. Repeating this information Discrepancies throughout submission may assist the FDA when they divide the submission among various sub-reviewers. Nonetheless, it is important to be consistent in these redundant sections.

5 Product Name Failure to follow guidance documents Missing performance testing data Usability Report Risk Management Missing clinical data The product name is likely to occur a hundred times throughout the submission, so ensure it is consistent throughout the documentation. In order to help medical device manufacturers determine what to include in their 510(k) applications, the FDA issues guidance documents or defers to national or international standards. All traditional 510(k) submissions must include performance testing data. FDA reviewers cannot determine substantial equivalence between your device and its predicate device without performance testing. Usability reports are an issue when the testing was not conducted as described in the guidance document. The consensus standard for risk management in the US is ISO 14971:2007. It requires a Risk Management Plan, a Risk Management Analysis, and a Risk Management Summary Report. The analysis is frequently a Failure Modes and Effect Analysis (FMEA) but other tools are also acceptable and must be submitted with the 510(k). Risk Analysis is a complex, time-consuming team activity. Allow plenty of time to complete this process and documentation before finalizing the 510(k) submission. For some device types, 510(k) submissions must include clinical performance data in order to evaluate substantial equivalence. If clinical data is submitted, there are forms that document if the investigator had any financial relationship with the sponsor, as well as the ClinicalTrials.gov form, which are required. Note that if clinical data is not submitted, these forms are no longer required.

6 Step (5): Clearance and Registration: Upon successful review of your 510(k) application, the FDA will send you a 510(k) clearance letter with your unique 510(k) number. In this letter they will note that your device is substantially equivalent to the predicate device outlined in your application. Keep in mind that the FDA does not approve medical devices through the 510(k) process - they clear them for sale. The only devices the FDA officially approves for sale are those that go through the PMA process. FDA 510(k) clearance requires you to implement and maintain a quality management system that complies with FDA Quality System Regulation (QSR). Once you receive your 510(k) clearance letter, you are subject to random inspection by the US FDA. Therefore, you must be in compliance with the QSR the day you receive FDA 510(k) clearance. If the FDA does inspect you and finds major deficiencies in compliance, they can issue a Warning Letter. This letter is made public on the FDA website in perpetuity, which is not optimal to those searching for your company name. The FDA 510(k) process is considerably more complex than it was previously. While it is significantly less burdensome than a Pre-Market Approval (PMA), the 510(k) is now more complex and comprehensive. Still, careful document preparation, following a known successful pathway, and clear communication with personnel preparing the submission will help ensure a more efficient clearance process for your device.

510(k) submissions. Getting US FDA clearance for your device: Improving

510(k) submissions. Getting US FDA clearance for your device: Improving Getting US FDA clearance for your device: Improving 510(k) submissions Audrey Swearingen, RAC Director, Regulatory Affairs Telephone: +1 512.222.0263 Email: aswearingen@emergogroup.com Download this white

More information

FDA 510(k) 101 The Basics

FDA 510(k) 101 The Basics FDA 510(k) 101 The Basics Floyd G. Larson President, PaxMed International San Diego, CA OMTEC June 17, 2010 Chicago Agenda History of 510(k) process FDA s risk based approach FDA guidance and standards

More information

Use of Standards in Substantial Equivalence Determinations

Use of Standards in Substantial Equivalence Determinations Guidance for Industry and for FDA Staff Use of Standards in Substantial Equivalence Determinations Document issued on: March 12, 2000 U.S. Department Of Health And Human Services Food and Drug Administration

More information

BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE. Yuan Xu 18- JAN- 2018

BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE. Yuan Xu 18- JAN- 2018 BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE Yuan Xu 18- JAN- 2018 Background AGENDA What is Medical Device? What is 510(k)? Principles of best practices of device

More information

TOBACCO PRODUCT OR MEDICAL PRODUCT?

TOBACCO PRODUCT OR MEDICAL PRODUCT? TOBACCO PRODUCT OR MEDICAL PRODUCT? Priscilla Callahan-Lyon, MD Deputy Director Division of Individual Health Science Office of Science, CTP Grail Sipes, JD Director Office of Regulatory Policy, CDER Disclaimer:

More information

Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA

Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA Document issued on: November 12, 2002 This document supersedes the

More information

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance

More information

Primer: Medical Device User Fee Amendments Han Zhong l September 2011

Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Primer: Medical Device User Fee Amendments Han Zhong l September 2011 Introduction The Medical Device User Fee and Modernization Act (MDUFMA or MDUFA) is a set of agreements between the Food and Drug Administration

More information

Overview of the Legal Framework for Medical Device Regulation in the United States

Overview of the Legal Framework for Medical Device Regulation in the United States 1 Overview of the Legal Framework for Medical Device Regulation in the United States Ellen J. Flannery This chapter provides an overview of the legal framework for medical device regulation in the United

More information

Ko0 -t. Exhibit 2 MAY 3 0? 510 (K) Summay. Company Name: Columbia Scientific Development, LLC 420 NW I Ith Ave., Suite 617 Portland, Oregon 97209

Ko0 -t. Exhibit 2 MAY 3 0? 510 (K) Summay. Company Name: Columbia Scientific Development, LLC 420 NW I Ith Ave., Suite 617 Portland, Oregon 97209 Ko0 -t Exhibit 2 MAY 3 0? 510 (K) Summay Company Name: Columbia Scientific Development, LLC 420 NW I Ith Ave., Suite 617 Portland, Oregon 97209 Contact: Stephen Shulman Phone: 734-663-0132 Fax: 734-663-1306

More information

Draft Guidance for Industry and FDA Staff

Draft Guidance for Industry and FDA Staff Draft Guidance for Industry and FDA Staff Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile DRAFT GUIDANCE This guidance document

More information

Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA Telephone: 510/

Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA Telephone: 510/ Department of Health and Human Services Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Telephone: 510/337-6700 WARNING LETTER December

More information

FDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update

FDLI s Enforcement, Litigation, and Compliance Conference. Center for Tobacco Products Office of Compliance and Enforcement 2017 Update FDLI s Enforcement, Litigation, and Compliance Conference Center for Tobacco Products Office of Compliance and Enforcement 2017 Update Ann Simoneau, Director Office of Compliance and Enforcement Center

More information

Raritan Pharmaceuticals, Inc. 6/20/17

Raritan Pharmaceuticals, Inc. 6/20/17 Raritan Pharmaceuticals, Inc. 6/20/17 U.S. Food & Drug Administration Division of Pharmaceutical Quality Operations I New Jersey District 10 Waterview Boulevard, 3rd Floor Parsippany, NJ 07054 June 20,

More information

NEURONETICS. 510(k) SUMMARY NEUROSTAR TMS THERAPY SYSTEM'

NEURONETICS. 510(k) SUMMARY NEUROSTAR TMS THERAPY SYSTEM' NEURONETICS 510(k) SUMMARY NEUROSTAR TMS THERAPY SYSTEM' 510(k) Owner: Neuronetics, Inc. DEC 1 6 Z008 1 Great Valley Parkway, Suite 2 Malvern, PA 19355 Phone: 610-640-4202 Fax: 610-640-4206 Company Contact:

More information

Our medtech experts are yours. 510(k)s for Connected Medical Devices.

Our medtech experts are yours. 510(k)s for Connected Medical Devices. Our medtech experts are yours. 510(k)s for Connected Medical Devices. David Amor, MSBE, CQA Principal, Medgineering david@medgineering.com www.medgineering.com Agenda. What is a 510(k)? How do we determine

More information

4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch

4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch Libia Lugo Drug Specialist San Juan District Office Investigations Branch The Food and Drug Administration (FDA) responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico,

More information

RE: Permits under the Arizona Pharmacy Act should not be required for dietary supplements

RE: Permits under the Arizona Pharmacy Act should not be required for dietary supplements Board Members Arizona State Board of Pharmacy 1616 W. Adams St., Suite 120 Phoenix, AZ 85007 c/o Kam Gandhi, PharmD Executive Director Arizona State Board of Pharmacy Via email: kgandhi@azpharmacy.gov

More information

Mobile Medical Devices Final Project Assignment Submittal of the MMDA 510(k)

Mobile Medical Devices Final Project Assignment Submittal of the MMDA 510(k) Mobile Medical Devices Final Project Assignment Submittal of the MMDA 510(k) [Base upon http://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarketsubmissions/prem arketnotification510k/ucm142651.htm

More information

2/17/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota

2/17/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ FDA Authority Medical Device Act of 1976 FDA Modernization Act of 1997 Federal Food, Drug and Cosmetic Act (FFDCA)

More information

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/ FDA Authority Medical Device Act of 1976 FDA Modernization Act of 1997 Federal Food, Drug and Cosmetic Act (FFDCA)

More information

FDA Regulation of Diagnostic Tests Jeffrey N. Gibbs Hyman, Phelps & McNamara, P.C. Washington, DC

FDA Regulation of Diagnostic Tests Jeffrey N. Gibbs Hyman, Phelps & McNamara, P.C. Washington, DC AIPLA Annual Meeting Joint Biotechnology Committee/ Special Committee on FDA Law Program October 21, 2010 Marriott Wardman Park Hotel Washington, DC FDA Regulation of Diagnostic Tests Jeffrey N. Gibbs

More information

In Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review

In Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review In Vitro Diagnostic Testing for Direct Oral Anticoagulants- Premarket Review Cardiac Safety Research Consortium December 3, 2015 Lea Carrington Division of Immunology and Hematology Devices Office of In

More information

January 7, Dear Ms. Chung:

January 7, Dear Ms. Chung: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 January 7, 2015 Jeisys

More information

ANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015

ANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015 DEPARTMENT OF HEALTH & HUMAN SERVICES Silver Spring, MD 20993 ANDA 060851 Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY 10970 Docket No. FDA-2011-P-0081

More information

Mitch Zeller, Director, Center for Tobacco Products, FDA September 19, 2013 Kansas Public Health Association

Mitch Zeller, Director, Center for Tobacco Products, FDA September 19, 2013 Kansas Public Health Association Regulatory Public Laws Compliance & Education Policies Science & Enforcement & Communications The FDA Center for Tobacco Products (CTP): Its Role in Reducing Tobacco Use Mitch Zeller, Director, Center

More information

Talon Compounding Pharmacy 10/3/17

Talon Compounding Pharmacy 10/3/17 Talon Compounding Pharmacy 10/3/17 Office of Pharmaceutical Quality Operations, Division II 4040 N. Central Expressway, Suite 300 Dallas, Texas 75204 October 3, 2017 CMS Case # 522630 VIA UPS EXPRESS WARNING

More information

Mini Summit XIV: Clinical Trial Disclosure and Results Reporting Liability under FDAAA, Section 801

Mini Summit XIV: Clinical Trial Disclosure and Results Reporting Liability under FDAAA, Section 801 Mini Summit XIV: Clinical Trial Disclosure and Results Reporting Liability under FDAAA, Section 801 Jarilyn Dupont, JD Director of Regulatory Policy, Office of Policy Office of Commissioner, U.S. Food

More information

General Wellness: Policy for Low Risk Devices Guidance for Industry and Food and Drug Administration Staff

General Wellness: Policy for Low Risk Devices Guidance for Industry and Food and Drug Administration Staff General Wellness: Policy for Low Risk Devices Guidance for Industry and Food and Drug Administration Staff Document issued on: July 29, 2016. The draft of this document was issued on January 20, 2015.

More information

Town and Country Compounding and Consultation Services, LLC 10/17/17

Town and Country Compounding and Consultation Services, LLC 10/17/17 Town and Country Compounding and Consultation Services, LLC 10/17/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973)

More information

Tobacco Product Applications: FDA Perspective

Tobacco Product Applications: FDA Perspective Tobacco Product Applications: FDA Perspective Matthew R. Holman, Ph.D. Director, Office of Science Center for Tobacco Products Disclaimer: This information is not a formal dissemination of information

More information

International Pharmaceutical Aerosol Consortium on Regulation and Science

International Pharmaceutical Aerosol Consortium on Regulation and Science International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org Submitted

More information

IRB review of device studies

IRB review of device studies Washington University School of Medicine Digital Commons@Becker 2011 Device Advice from the FDA 2011 Conferences 2011 IRB review of device studies Jonathan M. Green Washington University School of Medicine

More information

,,~ 30! Premarket Notification - SomnoMed MAS Flex "S"

,,~ 30! Premarket Notification - SomnoMed MAS Flex S 510(K) SUMMARY This summary of 510(k) safety and effectiveness infornation is being submitted in accordance with the requirements of 21 CFR 807.92. Submitter Information: SomnoMed Inc Date Summary Prepared:

More information

AFDO Conference June 9, Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide

AFDO Conference June 9, Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide AFDO Conference June 9, 2009 Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide Government Agencies 483 observations A violation of the FD&C Act involving

More information

/tj7-0zq0 510 (k) Summary P

/tj7-0zq0 510 (k) Summary P /tj7-0zq0 510 (k) Summary P Date Prepared: November 28, 2012 Sponsor Information: Pulsecor Limited DEC i 2o12 Level 2, 135 Morrin Road Auckland 1072, New Zealand Sponsor Contact: Andrew Lowe Telephone:

More information

Donald W. Guthner Orgenix, LLC Ill Hill Road. Douglassville, PA (888) ORGENIX ( ) (484) (FAX) Intramedullary Nails, Nails

Donald W. Guthner Orgenix, LLC Ill Hill Road. Douglassville, PA (888) ORGENIX ( ) (484) (FAX) Intramedullary Nails, Nails K070741 ~, SANATMETAL Manufacturer of Orthopaedic and Traumatologic Products H-3301, Eger Faiskola ut 5. Phone: +(36)36-512-900 Fax: +(36)36-512-932 e-mail: metalasanatmetal.hu 510(k) Statement of Summary

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 9 Inspections, Compliance, Enforcement, and Criminal Investigations Phoenix Medical Devices, LLC 9/29/2009 Department of Health and Human Services Public Health Service Food and Drug Administration

More information

The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))

The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j)) The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j)) January 12, 2011 Cristi Stark, MS Senior Regulatory Health Project Manager Office

More information

Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports (806)

Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports (806) Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports (806) Presented by: Cap Uldriks, FDA Daniel P. Olivier, CCS Page 1 Objectives Define regulatory reporting rules based

More information

RESULTS AT A GLANCE. FDA Oversight of Tobacco Manufacturing Establishments. HHS OIG Data Brief August 2017 OEI

RESULTS AT A GLANCE. FDA Oversight of Tobacco Manufacturing Establishments. HHS OIG Data Brief August 2017 OEI HHS OIG Data Brief August 2017 OEI-01-15-00300 FDA Oversight of Tobacco Manufacturing Establishments RESULTS AT A GLANCE The Tobacco Control Act authorized FDA to regulate domestic tobacco manufacturers

More information

Strengthening the Center for Devices and Radiological Health s 510(k) Review Process February 18, 2010

Strengthening the Center for Devices and Radiological Health s 510(k) Review Process February 18, 2010 Strengthening the Center for Devices and Radiological Health s 510(k) Review Process February 18, 2010 R. Glenn Neuman, Director of Scientific Affairs NWRSInc.@gmail.com NewWorldReg.com NWRS was founded

More information

Regulatory Submission Strategies and Outlines For Ultrasonic Surgical Devices: Contact and HIFU Systems UIA Symposium Ronald R.

Regulatory Submission Strategies and Outlines For Ultrasonic Surgical Devices: Contact and HIFU Systems UIA Symposium Ronald R. Regulatory Submission Strategies and Outlines For Ultrasonic Surgical Devices: Contact and HIFU Systems 2006 UIA Symposium Ronald R. Manna Regulation Governing Medical Devices Europe: Council Directive

More information

David L. Rosen, B.S. Pharm., J.D. Partner, Adv. and FDA Regulatory Practice Co-chair, Life Sciences Industry Team Washington, DC

David L. Rosen, B.S. Pharm., J.D. Partner, Adv. and FDA Regulatory Practice Co-chair, Life Sciences Industry Team Washington, DC SUCCESSFULLY DEALING WITH BUSINESS, REGULATORY AND IP CHALLENGES IN ISRAELI BIOMED COMPANIES: Current FDA Issues Impacting the Regulation of BioMed Companies David L. Rosen, B.S. Pharm., J.D. Partner,

More information

510(k) 21 Summary of Safety and Effectiveness

510(k) 21 Summary of Safety and Effectiveness 510(k) 21 Summary of Safety and Effectiveness This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirement of 21 CFR 807.92. Submitter's Identification:

More information

ATTACHMENT A AdvaMed Comments Draft-Guidance for Industry and FDA Staff -510(k) Modifications: Deciding When to Submit a 510(k) for a Change to an Existing Device Line(s) No. Line or lines numbers of the

More information

Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA.

Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA. Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; Final Guidance for Industry and FDA (Laser Notice 51) Document issued on: May 27, 2001 U.S. Department of Health

More information

Comments of the Patient, Consumer, and Public Health Coalition. Strengthening the Center for Devices and Radiological Health s 510(k) Review Process

Comments of the Patient, Consumer, and Public Health Coalition. Strengthening the Center for Devices and Radiological Health s 510(k) Review Process March 19, 2010 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Comments of the Patient, Consumer, and Public Health Coalition on Strengthening

More information

FDA s 510(k) Working Group

FDA s 510(k) Working Group Understing the Premarket Notification (510(k)) Process FDA s 510(k) Working Group Presentation to the Institute of Medicine March 1, 2010 Donna-Bea Tillman, Ph.D. Director, Office of Deice Ealuation U.S.

More information

Using Recall Data to Assess the 510(k) Process

Using Recall Data to Assess the 510(k) Process Using Recall Data to Assess the 510(k) Process Ralph F. Hall Distinguished Professor and Practitioner University of Minnesota Law School July 28, 2010 Acknowledgments 2 Disclosures 3 Agenda I. Research

More information

February 15, AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040

February 15, AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040 February 15, 2018 AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040 Re: K180137 Trade/Device Name: AtriCure cryoice cryo-ablation probe (CRYO3), AtriCure

More information

The proposed rule is significant, and the requirements and exceptions are complex. Key provisions of the proposal are described below.

The proposed rule is significant, and the requirements and exceptions are complex. Key provisions of the proposal are described below. ADVISORY Food & Drug FDA ISSUES PROPOSED RULE TO ESTABLISH A UNIQUE DEVICE IDENTIFICATION SYSTEM FOR MEDICAL DEVICES July 16, 2012 On July 11, 2012, the Food and Drug Administration (FDA) published in

More information

Determining Whether A Dietary Supplement Study Requires an Investigational New Drug (IND)

Determining Whether A Dietary Supplement Study Requires an Investigational New Drug (IND) Determining Whether A Dietary Supplement Study Requires an Investigational New Drug (IND) 02/02/16 description Does a study that claims their dietary supplement promotes healthy joints and cartilage or

More information

Slow The Old FDA Entangled in its own bureaucracy Alleged by some to be too friendly with the industry it was supposed to regulate 3 What is the Curre

Slow The Old FDA Entangled in its own bureaucracy Alleged by some to be too friendly with the industry it was supposed to regulate 3 What is the Curre HCCA Research Compliance Conference What Every Compliance Professional Should Know About Dealing With The FDA Neil F. O Flaherty OFW Law June 13, 2011 1 Key Take-Aways Insights into what s going on at

More information

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products UNITED STATES REGULATION OF TOBACCO PRODUCTS Presented by Mitch Zeller Center Director FDA Center for Tobacco Products May 24, 2016 OVERVIEW OF TODAY S PRESENTATION Highlights of the Deeming Final Rule

More information

NOV Jo 6) ' 510(k) Summary

NOV Jo 6) ' 510(k) Summary NOV 2 9 2004Jo 6) ' 510(k) Summary 1. Applicant Amest Corporation 303194 Espetranza Rancho Santa Margarita, CA 92688 Contact person: John Jest Amnest Corporation 30394 Espcranza Rancho Santa Margarita,

More information

UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP)

UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP) UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP) Mitch Zeller, J.D. Director, FDA May 4, 2017 CENTER FOR TOBACCO PRODUCTS AGENDA Update on Regulations and Guidances: Deeming Update on Science Update

More information

K Michael Kolber Regulatory Affairs

K Michael Kolber Regulatory Affairs 510(k) Number Submitter Name and Address Name: Contact: Address: Consultant, K122105 for the SM I Cardiovascular Patch November 7, 2012 Appendix 4: 510(k) Summary per (21CFRSO7.92) DEC 1 202 K122105 Michael

More information

Introduction. Current status of 510(k) clinical data requirements. 1 Current Status&Considerations:

Introduction. Current status of 510(k) clinical data requirements. 1   Current Status&Considerations: 510(k) Current Status&Considerations: Conducting a Well-Controlled Clinical Study When Clinical Data is Required Introduction In an effort to promote innovation while protecting the population at large,

More information

Medical Devices and the Public s Health: The FDA 510(k) Clearance Process at 35 Years. Written Statement of

Medical Devices and the Public s Health: The FDA 510(k) Clearance Process at 35 Years. Written Statement of Medical Devices and the Public s Health: The FDA 510(k) Clearance Process at 35 Years Written Statement of Dr. David R. Challoner Vice President for Health Affairs, Emeritus University of Florida and Chair,

More information

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Quick Facts Retailers that mix and prepare e-liquids or create or modify vaporizers

More information

March 8, DxNow, Inc. Kevin Sly Senior Advisor to DxNow, Inc. 401 Professional Drive, Suite 130 Gaithersburg, Maryland

March 8, DxNow, Inc. Kevin Sly Senior Advisor to DxNow, Inc. 401 Professional Drive, Suite 130 Gaithersburg, Maryland March 8, 2018 Kevin Sly Senior Advisor to 401 Professional Drive, Suite 130 Gaithersburg, Maryland 20879-3429 Re: Trade/Device Name: ZyMot ICSI Sperm Separation Device, ZyMot Multi Sperm Separation Device

More information

Hieber's Pharmacy 12/5/17

Hieber's Pharmacy 12/5/17 Hieber's Pharmacy 12/5/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 CERTIFIED MAIL RETURN RECEIPT REQUESTED

More information

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044 DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs

More information

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES COMPETENT AUTHORITY (UK) 10 EC MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES (CUSTOM MADE DEVICES) Updated March 2008 CONTENTS PAGE Introduction 3 Definition of dental

More information

Epoxy Curing Agents Used in Contact with Food or Potable Water

Epoxy Curing Agents Used in Contact with Food or Potable Water Epoxy Curing Agents Used in Contact with Food or Potable Water INTRODUCTION In the coatings industry, there are a number of applications where the coating needs to comply with regulations for safe use

More information

Purpose of this Document

Purpose of this Document Guidance on the Procedures for Joint Food Safety and Inspection Service (FSIS) and Food and Drug Administration (FDA) Approval of Ingredients and Sources of Radiation Used in the Production of Meat and

More information

5101K] SUMMARY [as required by (c)]

5101K] SUMMARY [as required by (c)] 735-10, Ancheong-dong, Gwangsan-gu, Gwangju, Korea FAX:+82-62-954-1055 http://www. inarex. co. kr IN AR E)( TEL:+82-62-952-1052 INAREX CORPORATION 5101K] SUMMARY [as required by 807.92(c)] AUG 2 7 2008

More information

Bacterin International Incorporated Mr. Howard L. Schrayer 600 Cruiser Lane Belgrade, Montana August 18, 2015

Bacterin International Incorporated Mr. Howard L. Schrayer 600 Cruiser Lane Belgrade, Montana August 18, 2015 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 Bacterin International

More information

FDA issues long-awaited final guidance on when a device modification requires a new 510(k)

FDA issues long-awaited final guidance on when a device modification requires a new 510(k) FDA issues long-awaited final guidance on when a device modification requires a new 510(k) November 2, 2017 Six years after its first attempt to update its 20-year-old guidelines for when modifications

More information

Overhauling The 510(k) Process

Overhauling The 510(k) Process Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Overhauling The 510(k) Process Law360, New York (August

More information

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Section III 510(k) Summary

Section III 510(k) Summary 510(k) Submission Report for Contec Pocket Fetal Doppler CD Y L- Internal Report SN: A2008-005-031 Section III 510(k) Summary As Required by CFR 807.92 FEB 2 5 2009 Sponsor: Contec Medical Systems Co.,

More information

February 15, AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040

February 15, AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040 February 15, 2018 AtriCure, Inc. Melissa Smallwood Regulatory Affairs Specialist 7555 Innovation Way Mason, Ohio 45040 Re: K180138 Trade/Device Name: AtriCure cryoice cryo-ablation probe (CRYO2) Regulation

More information

Residual Solvents: FDA/ Regulatory Perspective

Residual Solvents: FDA/ Regulatory Perspective Rosa Motta Compliance Officer Residual Solvents: FDA/ Regulatory Perspective PDA/USP Residual Solvents Conference January 18-19, 2007 1 Outline Laws and regulations governing the compliance requirements

More information

Key CDRH Regulatory Initiatives

Key CDRH Regulatory Initiatives Key CDRH Regulatory Initiatives Revamping the Submission Process Creating New Strategies Ralph F. Hall University of Minnesota Law School Counsel Faegre Baker & Daniels May 8, 2012 Purpose of Today s Program

More information

Appendix N Pilot Program Question and Answer Version 7.0 6/13/2018

Appendix N Pilot Program Question and Answer Version 7.0 6/13/2018 Appendix N Pilot Program Question and Answer Version 7.0 6/13/2018 This Q&A document answers questions that have been submitted to the NCIMS Appendix N Modification Study Committee. The start date for

More information

CDRH: 510(k)S AND SCIENCE IN REGULATOR DECISION-MAKING. lannery, Scott Danzis and Christopher Pruitt. November 2010 SPECIAL REPRINT

CDRH: 510(k)S AND SCIENCE IN REGULATOR DECISION-MAKING. lannery, Scott Danzis and Christopher Pruitt. November 2010 SPECIAL REPRINT November 2010 SPECIAL REPRINT CDRH: 510(k)S AND SCIENCE IN REGULATOR ORY DECISION-MAKING By Ellen Flanner lannery, Scott Danzis and Christopher Pruitt Reproduced with the kind permission of Global Regulatory

More information

Building better children s services: Concerns and complaints about childcare providers

Building better children s services: Concerns and complaints about childcare providers Building better children s services: Concerns and complaints about childcare providers Age group: 0 to 17 Published: July 2007 Reference no: 070154 Concerns and complaints about childcare providers Ofsted

More information

SECTION 2. SUMMARY AND CERTIFICATIOIov

SECTION 2. SUMMARY AND CERTIFICATIOIov SECTION 2. SUMMARY AND CERTIFICATIOIov 1 4 2 00 8 A. 510(K) SUMMARY.Summary of Safetv and Effctiveness In accordance with 21 CFR 807.92, the following information constitutes the Oticon Medical summary

More information

O(K) SUMMARY. Mega'Gen Co., Ltd , Eupchun-Ri, Jain-Myun. Gyeongsan, Gyeongbuk South Korea Phone: , Fax:

O(K) SUMMARY. Mega'Gen Co., Ltd , Eupchun-Ri, Jain-Myun. Gyeongsan, Gyeongbuk South Korea Phone: , Fax: EZ PLUS IMPLANT SYSTEM 13. 510O(K) SUMMARY Mega'Gen Co., Ltd. 114-8, Eupchun-Ri, Jain-Myun. Gyeongsan, Gyeongbuk South Korea Phone: 82-53-857-5770, Fax: 82-53-857-5432 510(K) Summary 510O(K) SUMMARY AND

More information

Guidance - IDE Early/Expanded Access for Devices

Guidance - IDE Early/Expanded Access for Devices Guidance - IDE Early/Expanded Access for Devices An unapproved medical device may normally only be used on human subjects through an approved clinical study in which the subjects meet certain criteria

More information

Draft Guidance for Industry and FDA Staff. Class II Special Controls Guidance Document: External Penile Rigidity Devices

Draft Guidance for Industry and FDA Staff. Class II Special Controls Guidance Document: External Penile Rigidity Devices Draft Guidance for Industry and FDA Staff Class II Special Controls Guidance Document: External Penile Rigidity Devices DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.

More information

Mark M. Yacura. Partner

Mark M. Yacura. Partner Mark M. Yacura Partner Mark M. Yacura focuses his practice primarily on FDA legal and regulatory matters. He has practiced in this area for more than 30 years. He represents his clients before administrative

More information

COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium

COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium COMMENTS on a draft Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation (Docket No. 99D-1454) Submitted by

More information

July 10, X-spine Systems, Incorporated David Kirschman, MD Chief Medical Officer 452 Alexandersville Road Miamisburg, Ohio 45342

July 10, X-spine Systems, Incorporated David Kirschman, MD Chief Medical Officer 452 Alexandersville Road Miamisburg, Ohio 45342 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service July 10, 2015 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 X-spine

More information

Border Issues and Statistics: Regulatory Activities. Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas

Border Issues and Statistics: Regulatory Activities. Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas Border Issues and Statistics: Regulatory Activities Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas U.S. Food & Drug Administration Mission Statement The Food & Drug Administration

More information

FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions

FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions FDA issues final guidance on benefit-risk factors to consider in medical device product availability, compliance, and enforcement decisions 23 January 2017 On December 27, 2016, the U.S. Food and Drug

More information

LEAF Marque Assurance Programme

LEAF Marque Assurance Programme Invisible ISEAL Code It is important that the integrity of the LEAF Marque Standard is upheld therefore the LEAF Marque Standards System has an Assurance Programme to ensure this. This document outlines

More information

About this consent form

About this consent form Protocol Title: Development of the smoking cessation app Smiling instead of Smoking Principal Investigator: Bettina B. Hoeppner, Ph.D. Site Principal Investigator: n/a Description of Subject Population:

More information

FDA Warning Letters Study

FDA Warning Letters Study FDA Warning Letters Study A Look at Warning Letters for Pharma/Biotech, Medical Device, and Food & Beverage Industries Since 2007 A Warning Letter is official correspondence that notifies the highest-ranking

More information

TELEMED. November 3, Engineering Manager Dariaus ir Gireno str. 42 Vilnius, LT LITHUANIA

TELEMED. November 3, Engineering Manager Dariaus ir Gireno str. 42 Vilnius, LT LITHUANIA DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 TELEMED Engineering Manager

More information

510(k) SUMMARY (Per 21 CFR ) MAY

510(k) SUMMARY (Per 21 CFR ) MAY K130498 page 1 of 3 General Company Information 510(k) SUMMARY (Per 21 CFR 807.92) MAY 3 12013 Name: Contact: Address: Howard Schrayer Regulatory Affairs Consultant 600 Cruiser Lane Belgrade, MT 59714

More information

Statement Of. The National Association of Chain Drug Stores. For. United States Senate Caucus on International Narcotics Control.

Statement Of. The National Association of Chain Drug Stores. For. United States Senate Caucus on International Narcotics Control. Statement Of The National Association of Chain Drug Stores For United States Senate Caucus on International Narcotics Control Hearing on: Improving Management 10:00 a.m. 226 Dirksen Senate Office Building

More information

EHR Developer Code of Conduct Frequently Asked Questions

EHR Developer Code of Conduct Frequently Asked Questions EHR Developer Code of Conduct Frequently Asked Questions General What is the purpose of the EHR Developer Code of Conduct? EHR Association (the Association) members have a long tradition of working with

More information

Agency Information Collection Activities; Submission for Office of Management and

Agency Information Collection Activities; Submission for Office of Management and This document is scheduled to be published in the Federal Register on 02/19/2019 and available online at https://federalregister.gov/d/2019-02596, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND

More information

MARKETING STANDARDS FOR MEMBERSHIP

MARKETING STANDARDS FOR MEMBERSHIP MARKETING STANDARDS FOR MEMBERSHIP The Vapor Technology Association (VTA) is a leading national trade association in the electronic cigarette and vapor product industry. VTA represents the manufacturers,

More information

Medical Device Regulatory Decision Points

Medical Device Regulatory Decision Points Medical Device Regulatory Decision Points Medical Device Classification Benefit Risk Regulatory Path Predicate Devices Valid Scientific Evidence Least Burdensome Approach Medical Devices Classified by

More information